Paricalcitol

FDA Drug Profile — Paricalcitol, Zemplar

Paricalcitol is listed in the FDA National Drug Code directory with 48 NDC codes, marketed under brand names including Paricalcitol, Zemplar. Available dosage forms: injection, solution, capsule, liquid filled, capsule, injection, powder.

Drug details

Generic Name
Paricalcitol
Brand Names
Paricalcitol, Zemplar
Application Number
NDA207174
Sponsor
Accord Healthcare, Inc.
NDC Codes
48
Dosage Forms
INJECTION, SOLUTION, CAPSULE, LIQUID FILLED, CAPSULE, INJECTION, POWDER
Routes
INTRAVENOUS, ORAL
Active Ingredients
PARICALCITOL

Indications and Usage

1 INDICATIONS AND USAGE Paricalcitol is a vitamin D analog indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with: Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis or peritoneal dialysis ( 1.2 ). 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD). Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.